In the last couple days, there was a run of interesting, comprehensive open access papers.
Most of these I saw while browsing Linked-In postings.
###
Bartolomucci et al. NPJ Precision Oncology (March 24 2025)
Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology.
https://www.nature.com/articles/s41698-025-00876-y
This paper reviews both MRD for drug monitoring and MRD for relapse.
###
Wang et al., Cancer Letters (May 1 2025)
Clinical development of immuno-oncology therapeutics.
https://www.sciencedirect.com/science/article/pii/S0304383525001806
###
Volders et al., NPJ Precision Oncology (March 10, 2025)
A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer. [Case study, Belgium]
https://www.nature.com/articles/s41698-025-00858-0
###
Matias-Guiu et al., Virchows Archiv (March 8, 2025)
Implementing digital pathology: qualitative and financial insights from eight leading European laboratories.
https://link.springer.com/article/10.1007/s00428-025-04064-y
Iwuajoku et al. Virchows Archiv (February 18 2025)
An equivalency and efficiency study for one year digital pathology for clinical routine diagnostics in an accredited tertiary academic center
https://link.springer.com/article/10.1007/s00428-025-04043-3
Zia et al., Virchows Archiv (February 12, 2025)
An update on applications of digital pathology: primary diagnosis; telepathology, education and research
https://link.springer.com/article/10.1186/s13000-025-01610-9
####
From the March 2025 CAP TODAY
- Liquid Biopsy's promise and complexities. Here.
- Generative AI in clinical pathology. Here.
- How patients view oncology path reports. Here.
- Negative view of private equity. Here.
